- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01795248
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Hellerup, Denmark, 2900
- Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for women with previous GDM:
- Informed oral and written consent
- Previous diagnosis of GDM according to current Danish guidelines (mainly PG concentrationa t 120 min after 75 g OGTT ≥ 9.0 mM) during pregnancy within the last 5 years
- Age >18 years
- 25 kg/m2 < BMI < 45 kg/m2
- NGT, IFG and or IGT
- Safe contraception and negative pregnancy test
Exclusion Criteria for women with previous GDM:
- Patients with diabetes
- HbA1c ≥6.5%
- Patients with previous pancreatitis or previous neoplasia
- Pregnant or breast feeding women
- Anaemia (haemoglobin <7 mM)
- Women planning to become pregnant within the next 5 years
- Women using other contraception than intrauterine device (IUD) or oral contraceptives. Women who do not use safe contraception will be offered application of an IUD.
- Women treated with statins, corticosteroids or other hormone therapy (except estrogens and gestagens)
- Ongoing abuse of alcohol or narcotics
- Impaired hepatic function (liver transaminases >3 times upper normal limit)
- Impaired renal function (se-creatinine >120 μM and/or albuminuria)
- Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)
- Any condition that the investigator feels would interfere with trial participation
- Receiving any investigational drug within the last 3 months
Inclusion criteria for women without previous GDM:
- Informed oral and written consent
- Age >18 years
- 25 kg/m2 < BMI < 45 kg/m2
- NGT
- Safe contraception and negative pregnancy test
- Pregnancy within the last ten years without GDM
Exclusion Criteria for women without previous GDM :
- Pregnant or breast feeding women
- Anaemia (haemoglobin <7 mM)
Inclusion Criteria for women without previous GDM and without NAFLD:
- Informed oral and written consent
- Age >18 years
- 25 kg/m2 < BMI < 45 kg/m2
- NGT
- At least one pregnancy witin the last ten years without GDM
Exclusion Criteria for women without previous GDM and without NAFLD:
- Pregnant or breast feeding women
- Anaemia (haemoglobin <7 mM)
- Steatosis as assessed by ultrasound scanning
- Recieving any investigational drug within the last 3 months
- Any condition that the investigator feels would interfere with the trial participation
Inclusion Criteria for women with biopsi-verified NAFLD:
- Informed oral and written consent
- Women with known NAFLD or NASH
- Age >18 years
- 25 kg/m2 < BMI < 45 kg/m2
- NGT
- At least one prior pregnancy
Exclusion Criteria for women with biopsi-verified NAFLD:
- women with established cirrhosis
- Pregnant or breast feedning women
- Anaemia (haemoglobin <7 mM)
- Women treated with statins, corticosteroids or other hormone therapy ( except oestrogens and gestagens)
- Ongoing abuse of alcohol or narcotics
- Impaired renal function (se-creatinine > 120 μM and/or albuminuria)
- Uncontrolled hypertension (systolic blood pressure > 180 mmHg, diastolic blood presure > 100 mmHg)
- Any condition that the investigator feels would interfere with trial participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liraglutide
1.8 mg liraglutide, subcutaneous, once-daily for five years
|
1.8 mg liraglutide
Other Names:
|
Placebo Comparator: Placebo
Placebo, subcutaneous, once-daily for one year
|
Liraglutide without the GLP-1 analogue
|
No Intervention: Control
Control without previous GDM.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glucose tolerance
Time Frame: from baseline to 52 wks, 53 wks, 260 wks, and 261 wks
|
Changes in glucose is measured by area under the curve for the plasma glucose excursion following a 4-hour 75 g oral glucose tolerance test (OGTT)
|
from baseline to 52 wks, 53 wks, 260 wks, and 261 wks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deterioration in glycaemic status
Time Frame: from baseline to 52 wks, 53, wks, 260 wks, and 261 wks
|
Percentage of subjects in each treatment arm with normal glucose tolerance (NGT) at inclusion who develop impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) or type 2 diabetes; or with IFG or IGT who develop combined IFG/IGT; or with combined IFG/IGT who develop type 2 diabetes
|
from baseline to 52 wks, 53, wks, 260 wks, and 261 wks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in glycated hemoglobin
Time Frame: From baseline to 52 wks and 260 wks
|
Changes in glycated hemoglobin (HbA1c).
From normoglycaemic to prediabetic or type 2 diabetic and from prediabetic to type 2 diabetic or normoglycaemic.
|
From baseline to 52 wks and 260 wks
|
Changes in anthropometric measurements
Time Frame: from baseline to 52 and 260 wks
|
Changes in body mass index (BMI)(kg/m2), absolute body weight (kg), and waist:hip ratio
|
from baseline to 52 and 260 wks
|
Changes in beta cell secretory responses
Time Frame: from baseline to 52, 53, 260, and 261 wks
|
changes in area under the curve during OGTT and isoglycemic intravenous glucose infusion (IIGI), the homeostatic model assessment (HOMA) and pro-insulin ratio
|
from baseline to 52, 53, 260, and 261 wks
|
Changes in insulin sensitivity
Time Frame: from baseline to 52, 53, 260, and 261 wks
|
assessed by HOMA-IR and Matsuda insulin sensitivity index
|
from baseline to 52, 53, 260, and 261 wks
|
Changes in incretin hormone secretion
Time Frame: baseline to 52, 53, 260, and 261 wks
|
measured as fasting plasma concentrations and plasma responses of GLP-1, GLP2, and GIP and plasma glucagon during OGTT
|
baseline to 52, 53, 260, and 261 wks
|
Changes in incretin effect
Time Frame: baseline to 52, 53, 260, and 261 wks
|
insulin and c-peptide responses after OGTT vs. IIGI
|
baseline to 52, 53, 260, and 261 wks
|
Changes in presence of non-alcoholic fatty liver disease (NAFLD)
Time Frame: baseline to 52 and 260 wks
|
gamma-glutamyltranferase (GGT), intra-heptic fat, FGF-21, whole body and visceral fat mass/fat-free mass, circulating lipids, ultrasound scan and fibroscan
|
baseline to 52 and 260 wks
|
Changes in cardio-metabolic risk measures
Time Frame: baseline to 52 and 260 wks
|
pro-collagen 3, GGT, Intra-hepatic fat, whole body and visceral fat mass/fat-free mass, circulating lipids and cardiovascular biomarkers (highly sensitive c-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), tumor necrosis factor-alpha (TNF-alpha), adiponectin and plasminogen activator inhibior-1 (PAI-1))
|
baseline to 52 and 260 wks
|
Changes in gut microbiota
Time Frame: baseline to 52 and 260 wks
|
optional to the main protocol
|
baseline to 52 and 260 wks
|
Changes in subjective appetite
Time Frame: baseline to 52, 53, 260, and 261 wks
|
visual analogue scale (VAS)
|
baseline to 52, 53, 260, and 261 wks
|
Number of participants with treatment-related adverse events (Safety and tolerability)
Time Frame: baseline to 52 and 260 wks
|
as assessed by validated questionnaires
|
baseline to 52 and 260 wks
|
Change in Quality of life
Time Frame: Baseline to 52 and 260 wks
|
Assessed by validated questionnaires (SF-36)
|
Baseline to 52 and 260 wks
|
Evaluation of alcohol consumption
Time Frame: baseline to 52 and 260 wks
|
By validated questionnaires
|
baseline to 52 and 260 wks
|
Evaluation of microalbuminuria
Time Frame: baseline to 52 to 260 wks
|
Predicitve value of biomarkers for detection of microalbuminuria
|
baseline to 52 to 260 wks
|
Evaluation of blindedness of participants and investigators
Time Frame: baseline to 52 wks
|
questionnaire and the end of the blinded trial
|
baseline to 52 wks
|
Changes in bonemarkers
Time Frame: baseline to 52 and 260 wks
|
baseline to 52 and 260 wks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tina Vilsbøll, MD, DMSc, University Hospital Gentofte
- Principal Investigator: Signe Foghsgaard, MD, PhD, University Hospital Gentofte
- Principal Investigator: Emilie Skytte Andersen, MD, PhD-student, Steno Diabetes Center Copenhagen
Publications and helpful links
General Publications
- Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum In: Lancet 1999 Aug 14;354(9178):602.
- Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. doi: 10.1038/sj.ijo.0801083.
- Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum In: Lancet. 2010 Mar 20;375(9719):984.
- Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum In: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322.
- Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998 Aug;21 Suppl 2:B161-7. No abstract available.
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006.
- Porte D Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci. 1999 Nov 18;892:73-83. doi: 10.1111/j.1749-6632.1999.tb07786.x.
- Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004 Mar;47(3):357-366. doi: 10.1007/s00125-004-1342-6. Epub 2004 Feb 13.
- Vilsboll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan Med Bull. 2004 Nov;51(4):364-70. No abstract available.
- Damm P, Vestergaard H, Kuhl C, Pedersen O. Impaired insulin-stimulated nonoxidative glucose metabolism in glucose-tolerant women with previous gestational diabetes. Am J Obstet Gynecol. 1996 Feb;174(2):722-9. doi: 10.1016/s0002-9378(96)70456-8.
- Jensen DM, Molsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, Damm P. Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study. Am J Obstet Gynecol. 2003 Nov;189(5):1383-8. doi: 10.1067/s0002-9378(03)00601-x.
- Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Molsted-Pedersen L, Hornnes P, Locht H, Pedersen O, Damm P. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004 May;27(5):1194-9. doi: 10.2337/diacare.27.5.1194.
- Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes. 2010 Oct;59(10):2625-30. doi: 10.2337/db10-0521. Epub 2010 Aug 3.
- Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med. 2002 May;19(5):351-8. doi: 10.1046/j.1464-5491.2002.00684.x.
- Bian X, Gao P, Xiong X, Xu H, Qian M, Liu S. Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus. Chin Med J (Engl). 2000 Aug;113(8):759-62.
- Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998 Aug;19(4):491-503. doi: 10.1210/edrv.19.4.0338.
- Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, Johnston DG. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia. 2011 Mar;54(3):641-7. doi: 10.1007/s00125-010-2009-0. Epub 2010 Dec 12.
- Foghsgaard S, Vedtofte L, Mathiesen ER, Svare JA, Gluud LL, Holst JJ, Damm P, Knop FK, Vilsboll T. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open. 2013 Oct 30;3(10):e003834. doi: 10.1136/bmjopen-2013-003834.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Pregnancy Complications
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetes, Gestational
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Liraglutide
Other Study ID Numbers
- GDM-TREAT
- 2012-001371-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes Mellitus
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
University of California, San FranciscoSan Francisco Department of Public Health; San Francisco General Hospital; Sonoma...CompletedType 2 Diabetes Mellitus | Gestational Diabetes MellitusUnited States
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingGestational Diabetes Mellitus in PregnancyFrance
-
i-Health, Inc.CompletedGestational Diabetes Mellitus in PregnancyGermany
-
The Danish Center for Strategic Research on Type...Odense University HospitalCompletedGestational Diabetes Mellitus in PregnancyDenmark
-
Services Institute of Medical Sciences, PakistanCompletedGestational Diabetes Mellitus in PregnancyPakistan
-
Danone Asia Pacific Holdings Pte, Ltd.Nutricia ResearchTerminatedGestational Diabetes Mellitus in PregnancySingapore
-
Federal State Budgetary Institution, V. A. Almazov...RecruitingGestational Diabetes Mellitus (GDM)Russian Federation
-
Athabasca UniversityCompletedDiabetes Mellitus Gestational Previous PregnancyCanada
Clinical Trials on Liraglutide
-
Woman'sNovo Nordisk A/SCompletedPolycystic Ovary Syndrome | Pre Diabetes | Obesity AndroidUnited States
-
Novo Nordisk A/SCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedTherapeutic EquivalencyChina
-
Merck Sharp & Dohme LLCCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Parker Research InstituteCompletedOsteoarthritis, KneeDenmark
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Henrik GudbergsenNovo Nordisk A/S; Cambridge Weight Plan LimitedCompleted
-
Henrik GudbergsenCompletedUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)Obesity | OsteoarthritisDenmark